PT1650219E - Homólogos de toll humana - Google Patents

Homólogos de toll humana Download PDF

Info

Publication number
PT1650219E
PT1650219E PT05023238T PT05023238T PT1650219E PT 1650219 E PT1650219 E PT 1650219E PT 05023238 T PT05023238 T PT 05023238T PT 05023238 T PT05023238 T PT 05023238T PT 1650219 E PT1650219 E PT 1650219E
Authority
PT
Portugal
Prior art keywords
human toll
pro286
pro285
pro358
proteins
Prior art date
Application number
PT05023238T
Other languages
English (en)
Portuguese (pt)
Inventor
Melanie R Mark
Audrey Goddard
Paul J Godowski
Austin L Gurney
Ruey-Bing Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27535565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1650219(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT1650219E publication Critical patent/PT1650219E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
PT05023238T 1997-10-17 1998-10-07 Homólogos de toll humana PT1650219E (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6225097P 1997-10-17 1997-10-17
US6531197P 1997-11-13 1997-11-13
US8332298P 1998-04-28 1998-04-28
US10541398A 1998-06-26 1998-06-26
US9086398P 1998-06-26 1998-06-26

Publications (1)

Publication Number Publication Date
PT1650219E true PT1650219E (pt) 2008-03-31

Family

ID=27535565

Family Applications (2)

Application Number Title Priority Date Filing Date
PT05023238T PT1650219E (pt) 1997-10-17 1998-10-07 Homólogos de toll humana
PT07020354T PT1887014E (pt) 1997-10-17 1998-10-07 Homëlogos de toll humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT07020354T PT1887014E (pt) 1997-10-17 1998-10-07 Homëlogos de toll humana

Country Status (11)

Country Link
EP (3) EP1650219B1 (enExample)
JP (3) JP4319348B2 (enExample)
AT (3) ATE314471T1 (enExample)
AU (1) AU1070399A (enExample)
CA (1) CA2305385C (enExample)
DE (3) DE69838888T2 (enExample)
DK (3) DK1650219T3 (enExample)
ES (2) ES2343210T3 (enExample)
IL (4) IL135345A0 (enExample)
PT (2) PT1650219E (enExample)
WO (1) WO1999020756A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696327B1 (en) 1997-10-17 2010-04-13 Genentech, Inc. Antibodies to human Toll homologues
ATE348157T1 (de) * 1997-05-07 2007-01-15 Schering Corp Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
AU2001264889B2 (en) * 1997-05-07 2006-06-29 Schering Corporation Human receptor proteins; related reagents and methods
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
JP2003533996A (ja) * 2000-05-25 2003-11-18 シェーリング コーポレイション ヒトレセプタータンパク質、関連試薬および方法
US6943240B2 (en) 2000-09-15 2005-09-13 Coley Pharmaceuticals Gmbh Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1293566A1 (en) * 2001-09-17 2003-03-19 Societe Des Produits Nestle S.A. A soluble toll-like receptor
EP2366389A1 (en) * 2002-04-08 2011-09-21 Takeda Pharmaceutical Company Limited Severe sepsis preventive therapeutic agent
EP2301564A1 (en) 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
CA2505843A1 (en) 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
CA2506356A1 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
WO2004094671A2 (en) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004247026B2 (en) * 2003-05-16 2009-09-24 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of CNS
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4562123B2 (ja) * 2003-06-17 2010-10-13 明治乳業株式会社 Ｔｏｌｌ様レセプター強制発現細胞の利用
WO2005001116A1 (ja) * 2003-06-17 2005-01-06 Meiji Dairies Corporation Toll様レセプター強制発現細胞の利用
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
ES2411504T3 (es) 2004-05-18 2013-07-05 Acorda Therapeutics, Inc. Métodos de purificación de condroitinasa y formulaciones estables de la misma
NZ550772A (en) * 2004-05-21 2009-10-30 Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2007051164A2 (en) 2005-10-27 2007-05-03 Centocor, Inc. Toll like receptor 3 modulators, methods and uses
WO2008036437A2 (en) * 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA3086902C (en) 2006-10-10 2021-11-09 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
SI2528598T1 (sl) 2010-01-27 2016-04-29 Takeda Pharmaceutical Company Limited Spojine za supresijo periferne živčne motnje, inducirane s sredstvom proti raku
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE348157T1 (de) * 1997-05-07 2007-01-15 Schering Corp Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
DE69931284T9 (de) * 1998-03-25 2007-10-18 Genentech Inc., San Francisco Menschliches Neurotrimin-Homolog

Also Published As

Publication number Publication date
EP1025227A2 (en) 2000-08-09
ES2298905T3 (es) 2008-05-16
AU1070399A (en) 1999-05-10
IL135345A0 (en) 2001-05-20
DK1025227T3 (da) 2006-05-01
EP1887014A1 (en) 2008-02-13
DK1887014T3 (da) 2010-08-02
PT1887014E (pt) 2010-07-05
DE69838888D1 (de) 2008-01-31
IL180967A (en) 2012-09-24
CA2305385A1 (en) 1999-04-29
ES2343210T3 (es) 2010-07-26
DE69838888T2 (de) 2008-12-11
JP4319348B2 (ja) 2009-08-26
EP1650219A1 (en) 2006-04-26
EP1650219B1 (en) 2007-12-19
ATE314471T1 (de) 2006-01-15
EP1887014B1 (en) 2010-04-07
DK1650219T3 (da) 2008-05-05
JP2002526028A (ja) 2002-08-20
DE69833014T2 (de) 2006-08-10
WO1999020756A2 (en) 1999-04-29
DE69833014D1 (de) 2006-02-02
JP5425244B2 (ja) 2014-02-26
IL180967A0 (en) 2007-07-04
ATE463502T1 (de) 2010-04-15
DE69841607D1 (de) 2010-05-20
JP2012105662A (ja) 2012-06-07
IL135345A (en) 2007-06-03
JP2009131265A (ja) 2009-06-18
JP5027105B2 (ja) 2012-09-19
IL221367A (en) 2015-06-30
ATE381574T1 (de) 2008-01-15
CA2305385C (en) 2013-05-21
EP1025227B1 (en) 2005-12-28
WO1999020756A3 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
IL180967A0 (en) Human toll homologues
IL131016A0 (en) Selection of proteins using rna-protein fusions
ATE329028T1 (de) Nl3 tie rezeptortyrosinekinase ligandhomologe
EP0832973A3 (en) GTP-binding protein
DE69839444D1 (de) Smad 6 und dessen anwendungen
IL161016A (en) Polypeptides capable of ang-2 binding
EP1517144A3 (en) Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor
EP1246686A4 (en) RAPID IDENTIFICATION OF PROTEINS USING ANTIBODY MIXTURES
WO1995024481A3 (en) Humanized monoclonal antibodies against human interleukin-4
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
GB9816514D0 (en) Novel method
EP0677115A4 (en) TIA-1 BINDING PROTEIN AND CODING, ISOLATED AND COMPLEMENTARY DNA.
GB2332906A8 (en) Nucleic acids encoding TTX-resistant Na channel proteins
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
WO1998002557A3 (en) MAMMALIAN TNF-α CONVERTASES
DE59712604D1 (de) Mittel zur identifizierung und therapie metastasierender tumore
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
EP0893501A3 (en) Ferrichrome transport atp-binding protein
WO2001021794A3 (en) Smad associating polypeptides